Allogene (NASDAQ: ALLO) details 2025 loss, pipeline data milestones and cash runway
Allogene Therapeutics reported its fourth quarter and full-year 2025 financial results, highlighting a net loss of $190.9 million or $0.87 per share for the year. The company provided updates on key pipeline milestones, including an interim futility analysis for the ALPHA3 trial of cema-cel in April 2026 and proof-of-concept data for the RESOLUTION trial of ALLO-329 in autoimmune disease in June 2026. Allogene ended 2025 with $258.3 million in cash, cash equivalents, and investments, extending its cash runway into the first quarter of 2028.
How this was made

The 30-second read
Why it matters
Upcoming trial data releases are critical; positive results could boost stock, while setbacks may lead to declines.
Market read
High relevance for biotech investors; moderate relevance for broader markets.
What to watch
Potential regulatory changes or partnership announcements could significantly alter the outlook.
Background
Allogene Therapeutics is advancing its CAR-T cell therapies with key clinical milestones scheduled for 2026.
Ticker impact
Primary focus due to recent financial results and pipeline updates.
Potential for moderate positive movement around milestone dates; however, overall impact remains uncertain due to financial losses.
Financial losses and upcoming clinical milestones create mixed signals; market reaction will depend on trial outcomes and investor sentiment.
Market effects
Biotech sector may experience volatility based on clinical trial outcomes and pipeline progress.
Limited; primarily affects US biotech stocks.
Low; company-specific news with minimal immediate global impact.
Counterpoint
Positive trial results could lead to a sharp rally, making this an opportunity for swing traders.
Key entities
- CompanyAllogene Therapeutics
Biotech company specializing in allogeneic CAR-T cell therapies.
- Clinical TrialALPHA3 trial
Interim futility analysis scheduled for April 2026.
- Clinical TrialRESOLUTION trial
Proof-of-concept data expected in June 2026.

